Welcome to our dedicated page for Ge Healthcare Technologies news (Ticker: GEHC), a resource for investors and traders seeking the latest updates and insights on Ge Healthcare Technologies stock.
GE Healthcare Technologies Inc (GEHC) delivers innovative medical technologies that shape global healthcare through advanced imaging, diagnostics, and patient care solutions. This page provides direct access to official company announcements, financial disclosures, and strategic developments.
Investors and industry professionals will find a centralized repository of GEHC news, including earnings reports, product launches, regulatory updates, and partnership announcements. All content is sourced from verified channels to ensure accuracy and timeliness.
Regular updates cover GEHC's advancements in medical imaging systems, AI-driven diagnostics, and healthcare digitization trends. Bookmark this page to monitor the company’s progress in addressing complex clinical challenges while maintaining compliance with global regulatory standards.
GE HealthCare (GEHC) announced a $138 million investment to expand its contrast media manufacturing facility in Cork, Ireland. The new 3000m2 state-of-the-art facility will increase production capacity by 25 million patient doses per year by the end of 2027.
The expansion aims to address the growing global demand for iodine-based contrast media, which is expected to double in the next decade. The investment includes solution preparation vessels, powder handling systems, a new filling line, and autoclaves with advanced automation systems.
The Cork facility, along with sites in Shanghai and Oslo, supplied over 100 million patient doses of contrast media in 2024. Construction will begin in February 2025, creating over 250 construction roles.
GE HealthCare (GEHC) has achieved a significant milestone by being named to the 2025 Fortune World's Most Admired Companies™ list for the first time since becoming an independent company. The recognition spans multiple categories, including management quality, products and services, innovation, investment value, and environmental responsibility.
The company's inclusion on this prestigious list reflects its successful implementation of the precision care strategy and its commitment to improving clinical workflows and patient outcomes. With 51,000 global colleagues, GE HealthCare continues to build upon its 125-year legacy of innovation in healthcare.
The ranking, considered the 'gold standard' for employee-centric companies, requires companies to score in the top half of their industry survey to be listed. This achievement validates GE HealthCare's entrepreneurial and inclusive culture, which focuses on delivering innovative healthcare solutions worldwide.
GE HealthCare (GEHC) has received FDA 510(k) clearance for its updated Voluson Expert Series ultrasound systems. The new series, comprising Voluson Expert 22, 20, and 18, combines high-resolution imaging with AI-powered features and automation tools designed for women's healthcare.
The systems feature Lyric Architecture for detailed imaging and include enhanced AI tools like SonoLyst for automated annotations and measurements during 11-14 week anatomical exams. Notable improvements include Graphicflow for blood flow visualization and upgraded tools like SonoPelvicFloor3.0, which reduces pelvic floor measurement exam time by 80%, and SonoAVCfollicle2.0 for improved follicle detection.
This development addresses a critical healthcare need, as approximately 30,000 to 50,000 women in the United States experience complex, high-risk pregnancies annually. The systems will be showcased at the SMFM 2025 Pregnancy Meeting in Denver.
UCSF and GE HealthCare have launched a Care Innovation Hub, a joint research collaboration focusing on three key areas: advanced medical imaging accessibility, non-invasive diagnosis of neurological diseases, and precision oncology. The partnership combines UCSF's clinical expertise with GE HealthCare's technical knowledge to develop innovative healthcare solutions.
The collaboration aims to develop automated imaging methods, including patient-specific MRI techniques that adapt in real-time, explore connections between various brain conditions including Alzheimer's disease, and advance quantitative imaging methods for monitoring patient response to radiopharmaceutical therapies (RPTs).
The research will be conducted at UCSF facilities in the San Francisco Bay Area, with goals of improving diagnosis, treatment, hospital operations, and ensuring more equitable access to care.
Sutter Health and GE HealthCare (GEHC) have announced a seven-year strategic Care Alliance partnership, representing one of GE HealthCare's largest enterprise collaborations. The partnership aims to enhance imaging services across Sutter's 300+ facilities serving 3.5 million patients in California.
The alliance focuses on implementing advanced AI-powered imaging technology including PET/CT, SPECT/CT, MRI, CT, X-ray, nuclear medicine, and ultrasound systems. Key technologies include GE HealthCare's Omni Legend PET/CT, StarGuide SPECT/CT, and Vscan Air™ SL ultrasound with Caption AI™ software.
The collaboration will support Sutter's expansion plans, including new care sites across Northern California and specialized centers for heart, vascular, cancer, and neuroscience care. The partnership includes workforce development programs through Sutter Health University, focusing on training technologists, nurses, and physicians while promoting diversity in healthcare staffing.
GE HealthCare (GEHC) has scheduled the announcement of its fourth quarter and full year 2024 financial results for Thursday, February 13, 2025, before market opening. The company's management team will host a conference call and webcast at 8:30 a.m. Eastern Time (7:30 a.m. Central Time) on the same day. Investors can access the live webcast through the company's investor relations website, where the earnings release, financial information, and webcast replay will also be made available.
GE HealthCare (GEHC) has unveiled three new deep learning image processing solutions at RSNA 2024: Sonic DL for 3D, Clarify DL, and TrueFidelity DL. These innovations aim to enhance image quality and reduce scan times in medical imaging.
Key highlights include Sonic DL for 3D, which can reduce MRI scan times by up to 86%, Clarify DL for enhanced bone SPECT image quality with 98% better image resolution in clinical evaluations, and TrueFidelity DL for improved cardiac CT imaging.
These solutions join GE HealthCare's existing Effortless Recon DL portfolio, addressing the growing need for improved diagnostic imaging, particularly important as the U.S. expects over two million new cancer cases in 2024.
GE HealthCare (GEHC) showcases its commitment to sustainability at RSNA 2024, highlighting progress in reducing environmental impact while advancing patient care. The company achieved a 13% reduction in greenhouse gas emissions in 2023 and recovered 7,375 imaging machines, resulting in over 15 million pounds of reused material.
Key sustainable innovations include the CT motion syringeless injector, which reduced plastic waste by 84.6% at UW-Madison, and energy-efficient systems like Revolution Apex with Energy Saving Mode 2.0, cutting power consumption by up to 80%. The company also introduced a manganese-based MRI contrast agent as an alternative to gadolinium, addressing environmental concerns.
GE HealthCare (GEHC) has submitted a 510(k) application to the FDA for CleaRecon DL, an AI-based technology designed to enhance cone-beam computed tomography (CBCT) image quality in interventional procedures. The technology aims to remove image streaks and improve image interpretation confidence. To be available on Allia™ Image-Guided Solutions Systems, it represents GE HealthCare's commitment to advancing CBCT adoption. Additionally, the company is introducing OnWatch Predict, a predictive monitoring system for interventional image-guided systems designed to forecast component failures and reduce unplanned downtime.
GE HealthCare (GEHC) has agreed to acquire the remaining 50% stake in Nihon Medi-Physics (NMP) from Sumitomo Chemical, aiming to assume full ownership of the Japanese radiopharmaceutical company. NMP, which generated revenues of 28.2B JPY (~$183M) in 2023, specializes in developing and manufacturing radiopharmaceuticals for SPECT and PET molecular imaging procedures. The company operates 13 manufacturing facilities and focuses on research and development of radiotracers and theranostics. The transaction, expected to close in early 2025 subject to regulatory approvals, will strengthen GE HealthCare's Pharmaceutical Diagnostics segment and enhance patient access to next-generation radiopharmaceuticals in Japan and Asian markets.
FAQ
What is the current stock price of Ge Healthcare Technologies (GEHC)?
What is the market cap of Ge Healthcare Technologies (GEHC)?
